NZ606828A - Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof - Google Patents

Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof

Info

Publication number
NZ606828A
NZ606828A NZ606828A NZ60682807A NZ606828A NZ 606828 A NZ606828 A NZ 606828A NZ 606828 A NZ606828 A NZ 606828A NZ 60682807 A NZ60682807 A NZ 60682807A NZ 606828 A NZ606828 A NZ 606828A
Authority
NZ
New Zealand
Prior art keywords
amino acid
acid sequence
sequence seq
region
staphylococcus aureus
Prior art date
Application number
NZ606828A
Inventor
Robert A Kramer
Kruif Cornelis A De
Mark Throsby
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of NZ606828A publication Critical patent/NZ606828A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Disclosed is a human monoclonal antibody, wherein said antibody comprises: - a heavy chain CDR1 region comprising amino acid sequence SEQ ID NO: 55; - a heavy chain CDR2 region comprising amino acid sequence SEQ ID NO: 56; - a heavy chain CDR3 region comprising amino acid sequence SEQ ID NO: 57; - a light chain CDR1 region comprising amino acid sequence SEQ ID NO: 58; - a light chain CDR2 region comprising amino acid sequence SEQ ID NO: 59; and - a light chain CDR3 region comprising amino acid sequence SEQ ID NO: 60; characterised in that said antibody has opsonic phagocytic killing activity against at least one strain of each of at least two different Enterococcus species and against at least one strain of Staphylococcus aureus, wherein the sequences are as defined in the complete specification. Also disclosed is the use of said antibody in the manufacture of a medicament for the diagnosis, prophylaxis, treatment, or combination thereof, of an enterococcal infection and/or a staphylococcal infection.
NZ606828A 2006-06-06 2007-06-05 Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof NZ606828A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US81154206P 2006-06-06 2006-06-06
EP06115013 2006-06-06
EP06116719 2006-07-06
EP06121258 2006-09-26
EP07103587 2007-03-06
NZ594945A NZ594945A (en) 2006-06-06 2007-06-05 Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof

Publications (1)

Publication Number Publication Date
NZ606828A true NZ606828A (en) 2014-08-29

Family

ID=45220170

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ594945A NZ594945A (en) 2006-06-06 2007-06-05 Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
NZ606828A NZ606828A (en) 2006-06-06 2007-06-05 Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
NZ572775A NZ572775A (en) 2006-06-06 2007-06-05 Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ594945A NZ594945A (en) 2006-06-06 2007-06-05 Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ572775A NZ572775A (en) 2006-06-06 2007-06-05 Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof

Country Status (5)

Country Link
KR (3) KR20170042376A (en)
CN (1) CN102731651B (en)
CA (1) CA2891316C (en)
EA (1) EA021767B1 (en)
NZ (3) NZ594945A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10738342B2 (en) * 2018-08-30 2020-08-11 Urinary Technologies, Inc. System for microbial species detection, quantification and antibiotic susceptibility identification
CN113493510A (en) * 2021-07-07 2021-10-12 上海交通大学 Bovine-derived single-chain antibody for resisting staphylococcus aureus LukD virulence factor and preparation and application thereof
CN114196586B (en) * 2021-12-20 2023-04-11 郑州大学 Enterococcus mundtii and application thereof in fermenting Chinese herbal medicines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6908994B1 (en) * 1999-05-10 2005-06-21 The Texas A&M University System Collagen-binding proteins from enterococcal bacteria
EP1470237A4 (en) * 2001-12-21 2006-02-01 Biosynexus Inc Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
EP1483292A4 (en) * 2002-02-21 2006-05-17 Univ Pavia Monoclonal antibodies that are cross-reactive against bacterial collagen binding proteins

Also Published As

Publication number Publication date
CN102731651A (en) 2012-10-17
EA021767B1 (en) 2015-08-31
KR20160003317A (en) 2016-01-08
CA2891316A1 (en) 2007-12-13
CA2891316C (en) 2020-07-21
KR20170042376A (en) 2017-04-18
KR20180072676A (en) 2018-06-29
EA201200182A1 (en) 2012-06-29
CN102731651B (en) 2015-02-04
NZ572775A (en) 2011-09-30
NZ594945A (en) 2013-03-28

Similar Documents

Publication Publication Date Title
NZ598063A (en) Gram-positive bacteria specific binding compounds
MX2020001873A (en) Binding agents.
AU2006226733A8 (en) Antibodies against CD38 for treatment of multiple myeloma
GEP20074222B (en) Antibodies to cd40
WO2005103084A3 (en) Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
TW200720289A (en) Antibodies against CCR5 and uses thereof
EA200970694A1 (en) PEHYLATED Fab ANTIBODY FRAGMENTS TO Aβ PEPTIDE
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
EP3530736A3 (en) Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
NZ597676A (en) Crystalline anti-hTNFalpha antibodies
NZ705848A (en) Anti-cd38 antibodies
NZ597046A (en) Use of alpha-toxin for treating and preventing staphylococcus infections
EA202091590A1 (en) ANTIBODIES AGAINST PD-L1 AND THEIR APPLICATION OPTIONS
NZ574978A (en) Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
GEP20135826B (en) Novel antibodies used to treat cancer
NZ624752A (en) Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
RU2011142183A (en) MEANS FOR TREATMENT OF RHEUMATOID ARTHRITIS
ATE497392T1 (en) THERAPY WITH ANTI-CD4 ANTIBODIES AND RADIATION
WO2018027124A8 (en) Anti-o2 antibodies and uses thereof
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
NZ606828A (en) Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
WO2007089470A3 (en) Antigen-binding proteins targeting s. aureus orf0657n

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 05 JUN 2017 BY MATTHEW POLGLASE

Effective date: 20150512

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUN 2018 BY CPA GLOBAL

Effective date: 20170428

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUN 2019 BY CPA GLOBAL

Effective date: 20180503

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUN 2020 BY CPA GLOBAL

Effective date: 20190502

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUN 2021 BY CPA GLOBAL

Effective date: 20200430

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUN 2022 BY CPA GLOBAL

Effective date: 20210429

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUN 2023 BY CPA GLOBAL

Effective date: 20220428

LAPS Patent lapsed